Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.

Dermatol Ther (Heidelb) · 2026 · PMC12936322 · PMID 41501565

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The pooled difference between tildrakizumab and risankizumab did not reach statistical significance, and no significant difference between treatments was observed at weeks 24–28.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.